Editas Drugs, Inc. (NASDAQ:EDIT) seventh Annual Evercore HealthCONx Convention December 3, 2024 1:20 PM ET
Firm Members
Erick Lucera – Govt Vice President and Chief Monetary OfficerCristi Barnett – Senior Vice President, Company Communications and Investor Relations
Convention Name Members
Liisa Bayko – Evercore ISI
Liisa Bayko
Okay, welcome everybody. That is Evercore’s Healthcare Convention. I am Liisa Bayko, considered one of this mid-cap analysts right here at Evercore, and I have been masking Editas as one of many gene modifying corporations that we have been working with over my time at Evercore, and it has been actually enjoyable to look at your progress. So wanting ahead to moving into it with Erick, CFO, and we’ve got IR right here as properly with Cristi. And so we’ll go forward and get began. Why do not we begin with giving us an organization overview.
Erick Lucera
Effectively thanks Liisa for having us. You guys have been an amazing companion with us through the years and with me personally for a very long time. So thanks. Honored to be right here.
So I would say the place Editas is one of the best ways to consider what the corporate is to assume alongside the traces of our three pillar technique. The primary which means Renocel, the second being our in vivo program, and the third being our out-licensing of our IP, which we consider as its personal little enterprise. So with respect to Renocel, as you will have seen, we just lately introduced our intention to discover a companion for that, and that’s ongoing. However we expect that it’s a very, excellent asset with respect to the place among the different sickle cell merchandise are. We predict we’ve got the potential for a best-in-class medication and we will have an replace in a little bit beneath per week at ASH subsequent week in San Diego. So in case you guys are there, Cristi will likely be
